Connected data gives you a clearer picture
At Evaluate we collect, calibrate and connect the pharmaceutical world's data.
Thought Leadership
Latest Report
Evaluate Vantage Report: US Approvals Under the Spotlight
On April 27-29, a three-day US advisory committee meeting convenes. Their objective is to scrutinise the accelerated approvals of certain anti-PD-(L)1 drugs whose confirmatory trials have failed. Will the US FDA's standards change after years of apparent leniency? 'US Approvals Under the Spotlight', the latest report from Evaluate Vantage,…
Report library
Evaluate Vantage Pharma, Biotech & Medtech 2020 in Review
Despite the initial shock of the COVID-19 pandemic, 2020 was a standout year for biopharma. The top 600 biopharma companies added $487bn in market capitalisation, and…
Evaluate Vantage 2021 Preview
Biopharma’s role in trying to bring the COVID-19 pandemic to an end has made household names of companies large and small, and cutting-edge technologies like mRNA…
Evaluate Vantage Pharma, Biotech & Medtech Half-Year Review 2020
Biopharma was not exempt from the initial shock of a global pandemic, but the worst projections have not happened and the initial beneficiaries have now emerged. After a…
Evaluate Pharma World Preview 2020, Outlook to 2026
This year's edition of the Evaluate Pharma World Preview arrives at a time when the global economy is reeling. The impact of COVID-19 has so far wiped $7.85bn off…
Evaluate Vantage COVID-19 Report
Biopharma and Medtech are leading the fight against COVID-19, but are not immune from the significant economic impact of the pandemic. The COVID-19 pandemic is having a…
